Emergent BioSolutions (NYSE:EBS) Upgraded at StockNews.com

by · The Cerbat Gem

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.

Several other research firms have also recently weighed in on EBS. Rodman & Renshaw restated a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark increased their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

Get Our Latest Analysis on EBS

Emergent BioSolutions Stock Down 9.3 %

NYSE:EBS traded down $0.86 during mid-day trading on Tuesday, hitting $8.41. 1,084,257 shares of the company’s stock were exchanged, compared to its average volume of 3,365,321. Emergent BioSolutions has a one year low of $1.42 and a one year high of $15.10. The business has a fifty day moving average price of $8.63 and a 200 day moving average price of $7.96. The company has a market cap of $455.65 million, a PE ratio of -2.11 and a beta of 1.57. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Hedge Funds Weigh In On Emergent BioSolutions

Institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Emergent BioSolutions during the first quarter valued at $57,000. BNP Paribas Financial Markets grew its position in Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock worth $414,000 after acquiring an additional 99,520 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Emergent BioSolutions in the 1st quarter valued at approximately $300,000. Vanguard Group Inc. raised its stake in shares of Emergent BioSolutions by 14.7% in the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after acquiring an additional 436,911 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Emergent BioSolutions by 22.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares during the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

(Get Free Report)

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

Featured Stories